Protein Tyrosine Kinase

Imatinib improves survival of CML patients in accelerated phase: A 48-month follow-up Imatinib melhora a taxa de sobrevida de pacientes com LMC na fase acelerada: Acompanhamento de 48 meses

Quality of life / Protein Tyrosine Kinase / Chronic myeloid leukemia / Survival Rate / Drug Therapy / Treatment Response / Therapeutic Use / Treatment Response / Therapeutic Use

Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer

Breast Cancer / Humans / Breast Cancer Early Detecion and Treatment / Female / Protein Tyrosine Kinase / Breast / Protein tyrosine phosphatase / Enzyme / Prognosis / Lymph Node / Protein Tyrosine Phosphatases / Mitotic Index / Case Control Studies / Breast / Protein tyrosine phosphatase / Enzyme / Prognosis / Lymph Node / Protein Tyrosine Phosphatases / Mitotic Index / Case Control Studies
Copyright © 2017 DADOSPDF Inc.